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Abstract
Background: Positive surgical margins are a strong prognostic marker of disease outcome following radical
prostatectomy, though prior evidence is largely from a PSA-screened population. We therefore aim to evaluate the
biochemical recurrence in men with positive surgical margins (PSM) after minimally-invasive radical prostatectomy
(MIRP) in a UK tertiary centre.
Methods: Retrospective study of men undergoing laparoscopic or robotic-assisted radical prostatectomy between
2002 and 2014. Men with positive surgical margins (PSM) were identified and their biochemical recurrence (BCR)
rate compared with men without PSM. The primary outcome measures were BCR rates and time to BCR. Cox
regression was used to estimate adjusted hazard ratios for biochemical recurrence rate (BCR), accounting for
potential confounders.
Results: Five hundred ninety-two men were included for analysis. Pre-operative D’Amico risk stratification showed
37.5%, 53.3% and 9.3% of patients in the low, intermediate and high-risk groups, respectively. On final pathological
analysis, the proportion of patients with local staging pT2, pT3a and pT3b was 68.8%, 25.2% and 6.1% respectively.
Overall positive margin rate was 30.6%. On multivariate analysis, the only pre-operative factor associated with PSM
was age >65years. Patients with PSM were more likely to have higher tumour volume and more advanced
pathological local stage. The BCR rate was 10.7% in margin-positive patients and 5.1% in margin-negative patients,
at median 4.4-year follow-up. Upon multivariate analysis, high pre-operative PSA and high Gleason group were the
only significant predictors of BCR (P<0.05).
Conclusions: In comparison to patients with negative surgical margins, those with PSM do not translate into worse
medium-term oncological outcomes in the majority of cases amongst our cohort. We found that high pre-
operative PSA and high Gleason group were the only significant predictors of BCR.
Background
Surgical margin status at pathological analysis after
radical prostatectomy for prostate cancer is a key metric
to define the oncological adequacy of prostate resection
[1]. With active surveillance considered the primary
management option for low-risk prostate cancer, radical
prostatectomy (RP) is increasingly being used for inter-
mediate or high-risk patients, as part of multi-modal
therapy [2]. Positive surgical margin (PSM) rates have
been associated with RP for higher-risk disease with
reported incidence between 11-48% [1–3]. PSM has
been highlighted as a risk factor for disease progression
after surgery and, as such, margin status has been incor-
porated as a component of multiple prostate cancer
outcome prediction models [4–6].
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In contemporary practice, patients with the finding of
PSM alone at RP can be managed with PSA surveillance,
adjuvant or salvage radiotherapy [7] or entered into clin-
ical trials (for example RADICALS) [1, 4]. For patients
with biochemical relapse (BCR) following RP, the
European Association of Urology advises the use of
salvage radiotherapy with at least 66Gy at a PSA level
of < 0.5ng/ml [8].
In a recent report regarding contemporary MIRP in
the UK, the authors reported a trend towards increasing
use of MIRP amongst patients with high risk disease,
but with a high positive surgical margin rate of 33.6%
amongst patients with pT3 disease [9]. However, longer-
term oncological outcome data following MIRP in the
UK are lacking. Furthermore, only a small percentage of
patients in the UK are diagnosed with prostate cancer by
PSA screening [10], in comparison to the widespread
adoption of routine PSA screening in USA and some
European countries [11]. Therefore, oncological out-
comes of RP in a relatively unscreened UK population
may be hypothesised to vary from those previously
reported for screened cohorts.
In this report we describe the PSM rates in a consecu-
tive series of patients undergoing minimally invasive
radical prostatectomy at a large UK tertiary referral
centre. We explore the factors predicting PSM and
assess the medium term oncological outcomes as
regards to biochemical recurrence rates.
Methods
Study population
Following approval by the local audit and research depart-
ment, consecutive patients undergoing minimally invasive
radical prostatectomy (MIRP - laparoscopic or robotic
assisted) at our institution (between January 2002 and April
2014) were identified from a departmental database. Ex-
cised specimens underwent centralised pathological review.
Patients undergoing open radical prostatectomy during this
period were excluded. Retrospective review of their medical
electronic records, histopathology data and biochemistry
investigations was conducted. Data extracted included pre-
operative parameters (demographics, PSA, prostate biopsy
Gleason score, clinical stage), operative details (technique
and whether lymphadenectomy was performed) and
postoperative radical prostatectomy pathology (presence
of positive surgical, tumour Gleason score, tumour
stage, tumour volume). Patients who had detectable
PSA (ie >0.1ng/mol) 12 weeks post-operatively, less than
12 months of follow-up or those for whom PSA follow-up
data were unavailable, were excluded from this study.
Follow-up and biochemical recurrence
PSA follow-up data were captured. BCR was defined as
undetectable PSA post radical prostatectomy, which
subsequently rose to ≥ 0.2ng/mol. For patients with
biochemical recurrence, the need and timing of adjuvant
therapy (if any) was recorded.
Statistical analysis
Patient and disease characteristics between patients
stratified by incidence of surgical margins and biochem-
ical recurrence were compared using the Chi square test.
Student’s T test was used to compare means and Mann-
Whitney U test was used to compare medians. Potential
co-variates including age, pre-operative PSA, Gleason
score, and tumour volume, were included in a Cox re-
gression model to estimate adjusted hazard ratios for
positive surgical margins and biochemical recurrence.
Kaplan-Meier survival curves were built using the time
of biochemical recurrence as a failure event. A false dis-
covery rate adjustment was applied for multiple compar-
isons. Results were deemed to be statistically significant
if p value was less than 0.05.
Results
The overall positive surgical margin rate was 30.6%
In total 592 men underwent minimally invasive radical
prostatectomy (MIRP) between 2002 and 2012. Median
age at MIRP was 63 years (IQR 58-67 years). Median
PSA at diagnosis was 7.9ng/ml (IQR 5.7-11.8ng/ml) and
median follow-up was 52.8 months (IQR 25.0-73.6
months). Demographic data is summarised in Table 1.
Pre-operative D’Amico risk stratification noted 37.5% of pa-
tients in the low-risk group, 53.3% in the intermediate-risk
group and 9.3% in the high-risk group. 393 patients under-
went laparoscopic RP (LRP) and 199 underwent robotic-
assisted RP (RARP). On final pathological analysis, the pro-
portion of patients with local staging pT2, pT3a and pT3b
was 68.8%, 25.2% and 6.1% respectively. Lymph node sam-
pling was performed on 41.7% patients (247 of 592), of
whom 19 patients (8.0%) had evidence of lymph node in-
volvement. Positive surgical margins (PSM) were identified
in 181/592 (30.6%) excised pathological specimens.
PSM was associated with older age but not biopsy
Gleason score
On univariate analysis (Table 1), the only preoperative
factors associated with PSM were patient age >65years
and PSA >10ng/ml. Patients with PSM were also more
likely to have higher Gleason score on final pathology,
higher tumour volume and more advanced pathological
local stage. The overall PSM was marginally higher follow-
ing RARP, as compared to LRP (36.2% vs 27.7%, p = 0.05).
There was no significant change in PSM over time
(LRP: p = 0.5; RARP: p = 0.4).
On multivariate logistic regression (Table 2), key
factors predictive of PSM were patient age >65 years
(OR 2.11, 95% CI 1.41-3.15), higher pT stage (pT3a OR
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2.69, 95% CI 1.73-4.18; pT3b OR 6.35, 95% CI 2.77-
14.57), larger tumour volume (OR 1.09, 95% CI 1.03-
1.16), and the use of a robotic-approach (OR 2.52,
95% CI 1.18-5.37).
The biochemical recurrence rate in PSM was 10.7%
PSA follow up data were available for 532 patients
(89.9% of the cohort, Fig. 1) at a median follow-up of
30.3 months (16.0 - 52.7). Of these, 42 patients had
detectable PSA post-operatively and were therefore
excluded. In comparison to patients with undetectable
PSA, these 42 patients tended to have more aggressive
disease (Additional file 1: Table S1).
The overall biochemical recurrence rate (BCR) was
6.7% with a median time to BCR of 13.3 (11.6-33.5)
months. Comparing PSM and NSM, the BCR at
median follow-up of 52.8 months (IQR 25.0-73.6
months) was 10.7% and 5.1% respectively (p 0.026,
Fig. 2). There was no difference in time to BCR between
patients with PSM and NSM with a median time to
Table 1 Patient & disease characteristics overall, stratified by surgical margin status
Variable Patients with positive margins Patients with negative margins Overall p value
N (%) 181 (30.6) 411 (69.4) 592
Patient age at time of surgery
Under 65 years 82 (45.3) 252 (61.3) 334 (56.4) 0.009
65 years and above 99 (54.7) 159 (38.7) 258 (43.6)
Pre-op PSA
0.0-9.9 103 (57.9) 276 (68.3) 379 (65.1) 0.03
10.0-19.9 58 (32.6) 110 (27.2) 168 (28.9)
20.0 and above 17 (9.6) 19 (4.5) 35 (6.0)
Missing 2 7 9
Gleason score on biopsy
Group 1 (GS 2-6) 81 (44.8) 191 (46.5) 272 (46.0) 0.5
Group 2 (GS 3+4) 74 (40.9) 165 (40.2) 239 (40.4)
Group 3 (GS 4+3) 20 (11.0) 35 (8.5) 55 (9.3)
Group 4 (GS 8) 3 (1.7) 16 (3.9) 19 (3.2)
Group 5 (GS 9-10) 3 (1.7) 4 (1.0) 7 (1.2)
Pathological Gleason score
Group 1 (GS 2-6) 26 (14.4) 117 (28.5) 143 (24.2) <0.001
Group 2 (GS 3+4) 92 (50.8) 218 (54.0) 310 (52.4)
Group 3 (GS 4+3) 33 (18.2) 40 (9.7) 73 (12.3)
Group 4 (GS 8) 20 (11.1) 31 (7.5) 51 (8.6)
Group 5 (GS 9-10) 10 (5.5) 5 (1.2) 15 (2.5)
Pathological tumour stage
pT2 89 (49.2) 318 (77.4) 407 (68.8) <0.001
pT3a 68 (37.6) 81 (19.7) 149 (25.2)
pT3b 24 (13.3) 12 (2.9) 36 (6.1)
Lymph node involvement 10 (11.8) 7 (4.6) 17 (7.2) 0.06
Tumour volume of excised specimen
Median (IQR) 3.9 (1.8-6.7) 2.02 (0.81-4.0) 2.4 (1.0-5.1) <0.001
Surgical approach
LRP 109 (60.2) 284 (69.1) 393 (66.4) 0.05
RARP 72 (39.8) 157 (30.9) 199 (33.6)
Post-operative PSA*
Biochemical recurrence (%) 15/140 (10.7) 18 of 350 (5.1) 33 of 490 (6.7) 0.045
Median time to BCR (in months, IQR)* 10.9 (3.7-24.5) 13.1 (4.9-37.7) 12.1 (4.9-31.4) 0.5
*PSA data available for 532 of 592 patients. 490 patients had undetectable PSA post-operatively
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Table 2 Logistic regression results with 95% CI & p values (what factors predict PSM)
Univariate analysis Multivariate analysis
Variable OR 95% CI p value OR 95% CI p value
Year of procedure
2002-2009 1.00 - - 1.00 - -
2010-2012 1.15 0.76-1.73 0.5 0.72 0.43-1.19 0.2
2013-2014 1.25 0.79-1.96 0.4 0.37 0.15-0.93 0.03
Patient age at time of surgery
Under 65 years 1.00 - - 1.00 - -
65 years & above 1.89 1.33-2.70 <0.001 2.11 1.41-3.15 <0.001
Pre-op PSA
0.0-9.9 1.00 - - 1.00 - -
10.0-19.9 1.41 0.96-2.09 0.2 1.05 0.67-1.65 0.8
20.0 and above 2.53 1.26-5.10 0.02 1.30 0.56-3.00 0.5
Gleason score on biopsy
Group 1 (GS 2-6) 1.00 - - 1.00 - -
Group 2 (GS 3+4) 1.06 0.72-1.54 0.8 0.75 0.48-1.17 0.2
Group 3 (GS 4+3) 1.35 0.73-2.47 0.4 0.86 0.43-1.69 0.6
Group 4 (GS 8) 0.44 0.13-1.56 0.3 0.22 0.05-0.90 0.04
Group 5 (GS 9-10) 1.77 0.39-8.08 0.6 0.86 0.15-4.89 0.9
Pathological tumour stage
pT2 1.00 - - 1.00 - -
pT3a 3.00 2.01-4.47 <0.001 2.69 1.73-4.18 <0.001
pT3b 7.15 3.44-14.85 <0.001 6.35 2.77-14.57 <0.001
Median tumour volume of excised specimen 1.16 1.10-1.22 <0.001 1.09 1.03-1.16 0.005
Surgical modality
LRP 1.00 - - 1.00 - -
RARP 1.48 1.03-2.13 0.08 2.52 1.18-5.37 0.02
Fig. 1 Flow diagram of study population
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BCR of 13.1 (10.8-29.3) months and 15.5 (12.0-37.7) re-
spectively (p 0.49).
Upon univariate analysis, pre-operative PSA greater
than 10ng/ml, larger tumour volume and PSM were as-
sociated with BCR (Table 3). However, upon multivariate
Cox regression analysis to adjust for potential con-
founders, higher pre-operative PSA and higher Gleason
group disease were associated with BCR (Additional file
1: Table S2). Of note, margin status was not associated
with development of BCR.
Discussion
This is the largest reported single-centre UK series of
oncological outcomes, including biochemical recurrence
rates, following MIRP. The overall PSM in this cohort of
592 patients was 30.6%. Upon adjustment for potential
confounders, the only variables associated with greater
incidence of PSM were older age at time of surgery, pT3
stage disease, higher tumour volume, and use of a RARP
approach.
Comparative data indicate that the incidence of posi-
tive margins is equivalent among the open, laparoscopic,
and RARP approaches [12]. A recent meta-analysis
reported a 15% mean rate of PSMs in RARP series pub-
lished between 2008 and 2011, with a range of 6.5–32%
[3]. PSM rates in contemporary series range between
10.4 to 31.1%. The largest report, by Wright et al, was
based on a database study of 65,633 patients having
radical prostatectomy. PSMs were reported in 21.2% of
cases and were more common in pT3a than pT2
tumours (44% vs 18%, p <0.001) and higher grade
tumours (28% vs 18%, p <0.001) [13]. Reported RARP
series have noted a PSM rate of 15.7-29.5% [9, 14–18].
Preoperative PSA, prostate volume on trans-rectal ultra-
sound, clinical T (cT) stage, and pathological stage
(pT2 vs pT3) have been reported as independent
predictors of the presence of any PSM, while cT stage
and biopsy Gleason score have been reported as pre-
dictors of posterolateral PSM [14, 15].
From a UK perspective, of all 2,163 radical prostatec-
tomies (54.6% laparoscopic and 19.6% RARP) entered in
the British Association of Urological Surgeons database
in 2011, the overall PSM was 42.3% with no difference
between laparoscopic (26.6%) and robotic (22.5%) cases
[19]. Our findings of PSM rates are comparable to pub-
lished reports on minimally invasive prostatectomy. We
do note however a higher PSM rate in patients undergo-
ing robotic surgery (36.2%) in our cohort and this may
be representative of a learning curve effect. It is worth
noting an increasing proportion of patients being offered
surgery for high-risk disease. A recent study of robotic
RP in this group was reported by Kang et al who re-
ported a 25.1% PSM rate, and that higher tumour stage
and volume were associated with PSM [20]. Further-
more, a recent UK series reported that accumulated ex-
perience with robotic RP was associated with a temporal
decrease in PSM rate (22.5% in 2005-2008 vs 19.8% in
2013-15), despite an increase in the proportion of pa-
tients having surgery for higher risk disease [9].
In our study, patients with PSM were more likely to
develop biochemical recurrence (10.7%) versus those
with negative margins (5.1%). The median time to BCR
for patients with PSM was 13.1 months. On multivariate
analysis, factors predicting biochemical failure were high
pre-operative PSA and higher pathological Gleason
group at MIRP. The oncological implications of a posi-
tive surgical margin at radical prostatectomy are difficult
to predict [1]. Nine large contemporary studies have
investigated the impact of PSMs on biochemical recur-
rence rates, metastatic progression and prostate-cancer
mortality (Table 4). Whilst all studies found PSMs to be
associated with a higher risk of BCR, data on time to
metastatic progression and death were less clear. In-
creased risk of PCa death was noted in men with posi-
tive compared with negative surgical margins, at 4.2 year
[13] and 10 year follow-up [21]. However, this impact
was fairly marginal relative to the impact of Gleason
score and tumour stage on pathological assessment of
the excised prostate [21]. From the literature, it is appar-
ent that PSM increases the risk of disease recurrence
but the range of risk and the time to event (death from
prostate cancer) are very wide, depending mostly on the
presence or absence of other risk modifiers. Even if the
risk is real, competing causes of mortality may obscure
the predictive value of PSMs for death due to PCa [1].
Biochemical recurrence is a marker of disease progres-
sion and associated with poor prognosis. Previous
reports of BCR in patients with PSM are variable due to
differing lengths of follow-up and surgical approach.
Studies with patients predominantly undergoing open
RP have reported a BCR rate of 26.7% at 6 years [22] to
Fig. 2 Kaplan Meier survival analysis of time to biochemical recurrence
stratified by margin status
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54.3% at 10 years [21]. In contrast, shorter follow-up
data is available for patients with PSM following MIRP,
with a BCR rate ranging from 6.2% at 1 year [14] to
29.0% at 6.3 years [23]. A recent multi-institutional
study reported outcomes of over 5000 patients following
RARP and reported BCR rates of 14.1% at a median
follow-up of 4.2 years [18]. Our results are within this
range and, based upon previous data, it is likely that
additional patients may go on to develop BCR at longer
follow-up.
The choice of therapeutic strategy for patients with
PSM remains controversial. Recent evidence suggests
that adjuvant radiotherapy may lead to a 50–60%
reduction in the risk of PSA progression in men with
pathologically advanced prostate cancer [24, 25].
However, not all men with PSMs are destined to have
treatment failure and indeed the majority of men with
isolated PSMs, with or without extra-prostatic exten-
sion, are cured after RP alone [1, 3]. Therefore,
recommending adjuvant radiotherapy to all men with
Table 3 Patient & disease characteristics of patients with PSM, stratified by biochemical recurrence at end of study period
Variable BCR-free BCR All PSMs p value
N (%) 125 (89.3) 15 (10.7) 140
Patient age at time of surgery
Under 65 years 60 (48.0) 7 (46.7) 67 (47.9) 0.4
65 years and above 65 (52.0) 8 (53.3) 73 (52.1)
Pre-op PSA
0.0-9.9 81 (64.8) 4 (26.7) 85 (60.7) 0.003
10.0-19.9 38 (30.4) 7 (46.7) 45 (32.1)
20.0 and above 6 (4.8) 4 (26.7) 10 (7.2)
Pathological Gleason score
Group 1 (GS 2-6) 20 (16.0) 0 20 (14.3) 0.4
Group 2 (GS 3+4) 59 (55.2) 8 (53.3) 77 (55.0)
Group 3 (GS 4+3) 18 (14.4) 5 (33.3) 23 (16.4)
Group 4 (GS 8) 13 (10.4) 2 (13.3) 15 (10.7)
Group 5 (GS 9-10) 5 (4.0) 0 5 (3.6)
Surgical approach
LRP 75 (60.0) 10 (66.7) 85 (60.7) 0.6
RARP 50 (40.0) 5 (33.3) 55 (39.3)
Tumour volume of excised specimen
Median (IQR) 3.7 (1.7-6.6) 5.1 (2.5-10.2) 3.8 (1.8-6.7) <0.001
Pathological tumour stage
pT2 67 (53.6) 5 (33.3) 72 (51.4) 0.4
pT3a 44 (35.2) 6 (40.0) 50 (35.7)
pT3b 14 (11.2) 4 (26.7) 18 (12.9)
Lymph node involvement 7 (13.5) 0 (0.0) 0 (11.5) 0.4
Margin location
Apex 33 (26.4) 4 (26.7) 37 (26.4) 0.4
Base 23 (18.4) 1 (6.7) 24 (17.1)
Multifocal 19 (15.2) 5 (33.3) 24 (17.1)
Other 50 (40.0) 5 (33.3) 55 (39.3)
Adjuvant therapy
Salvage radiotherapy 12 of 41 (29.3) 10 of 14 (64.1) 22 of 55 (40.0)
Radiotherapy & hormones 0 1 of 14 (7.2) 1 of 55 (1.8)
Missing 84 1 85
Note: Patients with detectable PSA or missing PSA data post-operatively were excluded
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isolated PSMs should be done with caution especially
when factoring in the added morbidity associated with
radiotherapy treatment.
Detectable PSA following radical prostatectomy is
often considered treatment failure. In our cohort, 7.9%
had detectable PSA post-operatively, and were excluded
from subsequent analyses. These patients tended to have
more aggressive disease and were more likely to have
had positive surgical margins (73.8% in patients with de-
tectable PSA, vs 28.6% in patients with undetectable PSA
post-operatively, p<0.001, Additional file 1: Table S1).
Similarly, Koulikov et al reported similar findings, whereby
patients with low-detectable PSA (>0.03 and <0.2ng/ml)
and PSA velocity >0.05ng/year, were more likely to have
positive surgical margins and an increased incidence of
biochemical recurrence [26]. These data suggest that men
with low-detectable PSA post-prostatectomy may be
divided into two groups based upon PSA velocity, those
with stable PSA who do not often develop biochemical
recurrence and those with unstable PSA who go on to
develop biochemical recurrence. There is some evidence
to suggest that this subgroup of patients may benefit from
adjuvant radiotherapy [27].
There are some limitations to this study due to retro-
spective design and lack of PSA follow-up data for all
patients. This is due to patients moving to their local
units for follow-up. While previous reports and ours
have predominantly focussed on reviewing the influence
of pre-operative and surgical factors on long-term out-
come, it is prudent to also note the potential impact of
pathological features at the tumour margin. Pathological
data regarding length of positive margin and grade
pattern at the margin have previously been reported to
predict BCR [28]. However, such data were not available
for inclusion in our study. Moreover, molecular and
biochemical features at tumour margins [29, 30] may
also impact long term oncological outcomes, and sub-
typing positive margins based upon such features may
provide a more effective method of identifying
patients with PSM likely to benefit from personalised
adjuvant therapies, as has been proposed for resection
of other malignancies [31]. Lastly, this is a consecu-
tive series of patients with an increasing volume of
MIRPs performed each year. Therefore, it is difficult
to accurately control for the effect of the learning
curve. However, we adjusted for year of procedure,
which may help adjust for this potential confounder
to some degree. Interestingly, our data compares well
to other series though we await the long-term matur-
ation of this cohort.
Conclusion
In comparison to patients with negative surgical margins,
those with PSM do not translate into worse medium-term
oncological outcomes in the majority of cases amongst
our cohort. We found that high pre-operative PSA and
Gleason grade group were the only robust predictors of
BCR.
Additional file
Additional file 1: Table S1. Patient & disease characteristics overall,
stratified by post-operative PSA status (detectable vs undetectable).
Table S2. Multivariate evaluation of factors predicting BCR at 5-year
follow-up using Cox regression. Results are reported as adjusted hazard
ratios, with 95% confidence intervals. (DOCX 20 kb)
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